(Updated - February 5, 2024 4:49 PM EST)

Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $4.20, $0.13 better than the analyst estimate of $4.07. Revenue for the quarter came in at $2.52 billion versus the consensus estimate of $2.51 billion.

GUIDANCE:

Vertex Pharma sees Q1 2024 revenue of $10.55-10.75 billion, versus the consensus of $10.61 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.

Earnings Guidance